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A paucity of novel acting antibacterials is in development to treat
the rising threat of antimicrobial resistance, particularly in Gram-
negative hospital pathogens, which has led to renewed efforts in
antibiotic drug discovery. Fluoroquinolones are broad-spectrum
antibacterials that target DNA gyrase by stabilizing DNA-cleavage
complexes, but their clinical utility has been compromised by
resistance. We have identified a class of antibacterial thiophenes
that target DNA gyrase with a unique mechanism of action and
have activity against a range of bacterial pathogens, including
strains resistant to fluoroquinolones. Although fluoroquinolones
stabilize double-stranded DNA breaks, the antibacterial thiophenes
stabilize gyrase-mediated DNA-cleavage complexes in either one
DNA strand or both DNA strands. X-ray crystallography of DNA
gyrase–DNA complexes shows the compounds binding to a protein
pocket between the winged helix domain and topoisomerase-
primase domain, remote from the DNA. Mutations of conserved
residues around this pocket affect activity of the thiophene inhibi-
tors, consistent with allosteric inhibition of DNA gyrase. This drug-
gable pocket provides potentially complementary opportunities for
targeting bacterial topoisomerases for antibiotic development.
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The antibiotic era, heralded by the advent of penicillin, has ledto a long-standing improvement in global human health. The
wide range of antibacterial agents discovered from the 1940s to the
early 1960s enabled efficient treatment of an extensive range of
infections and was a key contributor to many aspects of modern
clinical care, such as wound care, surgery, and organ trans-
plantation. However, the rise of multidrug-resistant (MDR) strains
of pathogens, combined with the limited number of novel anti-
bacterials discovered since the 1960s, has resulted in a marked rise
in the rate of untreatable infections. The issue is especially acute
for MDR Gram-negative pathogens, which are exerting a signifi-
cant strain on health systems worldwide (1, 2). Efforts to identify
and optimize novel mechanism-of-action antibacterials to cope
with the current limited pipeline are thus of high importance.
Furthermore, many multinational pharmaceutical companies have
withdrawn from antibacterial research due to, among other rea-
sons, a perceived lack of commercial return of investment (3).
Recently, several calls for renewed and concerted efforts in anti-
biotic discovery have been made (4, 5). One response to this urgent
need is the New Drugs for Bad Bugs (ND4BB) suite of projects
launched by the Innovative Medicines Initiative (IMI), a public–
private partnership (6). We [GlaxoSmithKline (GSK)] have iden-
tified a series of DNA gyrase inhibitors that bind to a site on the
gyrase enzyme and have determined that the mode of action both
is distinct from known DNA gyrase antibacterials and has no cross-
resistance to currently used topoisomerase-targeting antibacterials.
This series was further developed in a collaborative effort within
the IMI-funded European Gram-negative Antibacterial Engine
(ENABLE) project (6), an academic–industry open-innovation
partnership for antibacterial discovery that is a component of the
ND4BB platform.
Bacterial type II DNA topoisomerases [DNA gyrase and DNA
topoisomerase (topo) IV] are among the few clinically validated
targets for antibacterial therapy (7, 8). These enzymes modulate
bacterial chromosome topology by performing transient double-
strand DNA cleavage via a covalent link between a tyrosine side
chain of the enzyme and a 5′ phosphate of DNA, followed by
strand passage and religation (9, 10), thereby either relaxing su-
percoils, decatenating, or introducing negative supercoils in DNA.
The highly successful fluoroquinolone (FQ) class of antibiotics,
exemplified by ciprofloxacin (Fig. 1D), target the DNA-cleavage
active site located at the “DNA gate” of these enzymes and in-
terfere with DNA religation, thereby converting the enzyme–DNA
complex into a “cleavage complex” that can release highly lethal
DNA double-strand breaks (11). This phenomenon is commonly
referred to as “poisoning” and is thought to underlie the efficiency
and, ultimately, the clinical success of the FQ antibiotics (11, 12).
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Balanced dual targeting of these highly related bacterial enzymes
is attractive from a drug discovery perspective due to the resulting
lower propensity for the development of antibiotic resistance.
Unfortunately, despite this dual targeting, the rise of clinical re-
sistance to FQs, most commonly by mutation in the conserved
GyrA S83 and D87 amino acid residues (Escherichia coli num-
bering), has compromised the use of this important class of anti-
biotics, especially in infections caused by Gram-positive and
-negative pathogens (13) and in MDR tuberculosis (14).
Two new classes of antibacterial agents targeting bacterial top-
oisomerases triazaacenaphthylenes and spiropyrimidinetriones are
currently in clinical trials. In the Novel Bacterial type II Top-
oisomerase Inhibitor (NBTI) class (15, 16), the triazaacenaphthylene
gepotidacin is in phase II clinical trials (17). Gepotidacin inhibits
these enzymes by bridging the DNA and topoisomerase at a site
midway between the two DNA-cleavage sites (15). This NBTI-
binding site is different from the FQ-binding sites, and gepotidacin
retains minimum inhibitory concentration (MIC) activity against FQ-
resistant strains (16). The spiropyrimidinetriones, exemplified by
ETX0914, also in phase II trials, bind the topoisomerase complex at
a site that overlaps with that of FQs, but remains effective against
FQ-resistant strains (18, 19). In contrast to the FQ, triazaacenaph-
thylene, and spiropyrimidinetrione classes, which all bind to the
DNA gate, the aminocoumarins, represented by novobiocin, target
the gyrase ATPase domain. Besides the FQs, novobiocin represents
the only other gyrase inhibitor class that has been approved for use
in the clinic although it was later withdrawn (for other classes of
topoisomerase inhibitors, see ref. 7). The focus of our work was the
identification of a new druggable pocket to target gyrase, which has
the potential to deliver new antibacterials without cross-resistance to
fluoroquinolones. Here, we describe the identification of a series of
DNA gyrase inhibitors with broad-spectrum antibacterial activity.
Although not drug candidates in their own right, characterization of
these inhibitors has led further to the discovery of a previously un-
exploited site for inhibition of gyrase. Unlike other topoisomerase II
poisons, these inhibitors do not make direct contact with DNA, in-
dicating an unforeseen allosteric mechanism for DNA-cleavage com-
plex stabilization.We also present biochemical data suggesting that this
mechanism is distinct from the poisoning of DNA gyrase by the FQs.
We discuss the potential implications for further drug-targeting en-
deavors and for the mechanism of DNA cleavage by DNA gyrase.
Results
Discovery and Characterization of DNA Gyrase Inhibitor Compound 1.
High-throughput screening (HTS) efforts have generally had limited
success in identifying antibacterial hits (20, 21). However, an HTS of
the GSK compound library measuring the DNA-dependent ATPase
activity of E. coli DNA gyrase, and confirmation of hits using bio-
chemical and genetic tools, led to the identification of the thiophene
1 [N-(2-amino-1-phenylethyl)-4-(1H,2H,3H-pyrrolo[2,3-β]pyridin-3-
yl)thiophene-2-carboxamide] (Fig. 1A) as a weak (IC50 = 5 μg/mL)
inhibitor of DNA gyrase. This compound inhibited the ability of
gyrase to introduce negative supercoils in relaxed DNA (Fig. 2A and
SI Appendix, Table S3) and stabilized gyrase-mediated DNA-
cleavage complex formation in vitro, consistent with a gyrase poi-
soning mechanism (Fig. 2B). Beyond activity at the target level,
compound 1 was shown to have MICs against both Gram-positive
(e.g., Staphylococcus aureus and Streptococcus pneumoniae) and
Gram-negative (e.g., E. coli and Pseudomonas aeruginosa) bacterial
pathogens, with significantly greater activity against strains in which
genes for major efflux systems (22) had been inactivated (Table 1).
To further evaluate the mechanism of action of compound 1, we
monitored the incorporation of radiolabeled, pathway-specific pre-
cursors (23) in an efflux-deficient strain of E. coli. In this assay,
compound 1 primarily inhibited the incorporation of 14C-thymidine,
similar to the behavior of another DNA-synthesis inhibitor, cipro-
floxacin (SI Appendix, Fig. S1).
The Compound-Binding Pocket Is Remote from DNA. In parallel with
the biochemical and genetic studies, we explored cocrystalliza-
tion of the inhibitor with DNA gyrase. We have found that the S.
aureus DNA gyrase crystallography platform can be used to gain
structural information on compounds that target both Gram-
positive and Gram-negative organisms (15, 19, 24). Using this
crystallographic platform, we obtained a 1.98-Å structure of
compound 1 complexed to an S. aureus DNA gyrase core fusion
[lacking the gyrase A (GyrA) C-terminal domain, the gyrase B
(GyrB) Greek-key domain, and the GyrB N-terminal domain]
and DNA (Fig. 3 and SI Appendix, Table S1 and Fig. S2). These
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Fig. 1. Chemical structures of compounds. (A) Compound 1. (B) Compound
2. (C) The NBTI GSK945237. (D) The fluoroquinolone ciprofloxacin.
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Fig. 2. Characterization of activity of compound 1 against DNA gyrase.
(A) Inhibition of E. coli DNA gyrase supercoiling activity by compound 1. Relaxed
(Rel) pBR322 DNA was incubated with gyrase and different concentrations of
compound and separated by agarose gel electrophoresis. (B) Stabilization of the
cleavage complex with E. coli DNA gyrase by compound 1. Supercoiled pBR322
DNA was incubated with gyrase and different concentrations of compound
1. Cleaved DNA complexes were trapped with SDS, followed by proteinase K
digestion, and DNA was separated by agarose gel electrophoresis. L, linearized
DNA; N, nicked DNA; SC, supercoiled DNA.
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structural data showed that compound 1 bound to the protein at a
site remote from the DNA-cleavage site and devoid of any direct
DNA contacts. As far as we know, neither of these features has
been previously reported in topoisomerase II poisons (15, 19, 25,
26). The binding pocket lies at the interface between the GyrB
topoisomerase-primase (TOPRIM) domain (27) and GyrA winged
helix domain (WHD) and opens as a groove toward the outer side
of the enzyme (Fig. 3 A–D). The residues contacting the inhibitor
are conserved across key pathogenic bacteria and, importantly, are
not found in human topoisomerase IIα or IIβ (Fig. 4A and SI Ap-
pendix, Table S2).
Structure-Guided Optimization of Compound 1 Produced a More
Active Lead Compound 2. Examination of the contacts between
compound 1 and the protein in the cocrystal structure revealed a
small hydrophobic cavity (Fig. 3C). We hypothesized that filling
this cavity would improve inhibitor binding and activity. Because
the position of the sulfur atom in compound 1 would not allow
appropriate substitution, we prepared a number of regioisomeric
analogs both with and without methyl groups designed to fill the
cavity. In parallel, we discovered that the azaindole of compound
1 could be replaced by a 2-chlorophenyl group.
This chemistry campaign resulted in lead compound 2 (Fig.
1B), which possessed increased activity against E. coli DNA
gyrase (SI Appendix, Table S3), as well as improved MIC against
E. coli strains (up to ∼32-fold compared with inhibitor 1) (Table 1).
A crystal structure of compound 2 bound to the same gyrase core
supported the original hypothesis that an added methyl group
would pack more tightly against the protein (Figs. 3 E and F and
4B and SI Appendix, Fig. S2). Additional optimization of com-
pound 2 was attempted within the IMI ENABLE consortium,
however work on the series was discontinued due to toxicity
findings.
Compounds 1 and 2 Do Not Show Cross-Resistance with Fluoroquinolones.
Importantly, compounds 1 and 2 showed no cross-resistance to high
level, FQ-resistant E. coli and Klebsiella pneumoniae strains carrying
the most common mutations found in clinical strains (Table 1). In
contrast, ciprofloxacin showed up to a 16,000-fold MIC increase with
FQ-resistant mutants compared with WT. The mechanism of action
of both compounds 1 and 2 was further confirmed as DNA gyrase
inhibition by isolation and identification of E. coli mutants re-
sistant to compound 1 and its analogs with mutations that
mapped to this enzyme (Table 1 and SI Appendix, Table S4),
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Fig. 3. Crystal structures of compounds 1 and 2 with S. aureus DNA gyrase and DNA. (A) Compound 1 binds in a pocket between the GyrA (cyan) and GyrB
(pink) subunits in the complex with DNA (green) and S. aureus GyrB27A56. (B) Orthogonal view of complex with protein shown in schematic and one GyrB-
GyrA subunit in pink and cyan and the other in gray. Carbon atoms of compound 1 are in red. (C) An enlarged view of the ligand binding site looking from
GyrB (R630 and E634 are near the viewer). A semitransparent surface on the protein is shown gray on the inside (view from GyrB) and colored on the outside.
Note that the front clipping plane cuts through the near surface at one point—allowing a clearer view of the “hydrophobic cavity” under the compound
(indicated with *). GyrA P343 is behind the far surface of the pocket. An Fo-Fc ligand omit map at 3.5 sigma (green mesh) is shown. Note that DNA is remote
from the compound binding site. (D) Orientation schematic showing the location of the compound 1 binding site (same view and color scheme as in B). The
dashed delineated domains are absent from the crystallographic core construct, and their approximate orientation is indicated. (E and F) Two orthogonal
views of the 2.22-Å crystal structure of compound 2 with S. aureus DNA gyrase, DNA, and GSK945237 (orange spheres, an NBTI used to cocrystallize and aid
crystallography) (Materials and Methods). The protein subunits are shown with semitransparent surface so that the thiophene (red spheres) can be seen. The
DNA is colored black/green to indicate the positions of the four base pair staggered breaks.
E4494 | www.pnas.org/cgi/doi/10.1073/pnas.1700721114 Chan et al.
and through biochemical characterization of these resistant-
mutant proteins (SI Appendix, Fig. S3 and Table 2).
The propensity for target-mediated resistance to these inhib-
itors in E. coli, Acinetobacter baumannii, and K. pneumoniae was
found to be modest (frequency of spontaneous resistance at four
times above the MIC was ∼1.8 × 10−8). The resistant mutants in
E. coli generated in these experiments conferred up to eightfold
MIC increase to compound 1 and ∼32-fold MIC increase to
compound 2 compared with the parent strain (Table 1 and SI
Appendix, Table S4). In contrast, ciprofloxacin showed no
(E793K mutant) (Table 1) or little (up to fourfold) (SI Appendix,
Table S4) cross-resistance to the thiophene series-resistant mu-
tants generated. Genetic characterization of these mutants by
PCR and DNA sequencing revealed that several had altered
amino acids that were located in or close to the thiophene-
binding pocket (SI Appendix, Tables S2 and S4 and Fig. 4).
Laboratory-Generated Resistant Mutants Confirmed the Biological
Relevance of the Thiophene Compound-Binding Site. Mapping the
laboratory-generated resistant mutants revealed that three of
these mutants, E. coli GyrB-E793K, GyrB-R789, and GyrA-P342
(equivalent to E634, R630, and P343 in S. aureus, respectively)
directly contact compounds 1 and 2 in the crystal structures
(Figs. 3C and 4). Furthermore, resistant mutants selected to
compound 2 in an A. baumannii efflux-deficient strain mapped
to gyrase residues located in or adjacent to this binding pocket
(SI Appendix, Table S4), which supported the relevance of the
structure in understanding the mode of action of these com-
pounds and the biochemical validity of this binding pocket.
To obtain independent, biochemical confirmation of the rel-
evance of this binding site, we overexpressed, purified, and
characterized DNA gyrase that carries a mutation in a key res-
idue for inhibitor binding (E. coliGyrB-E793K) (Fig. 4). Using in
vitro gyrase supercoiling inhibition assays, compound 2 dis-
played >100-fold less activity against this mutant enzyme com-
pared with the WT enzyme (Table 2 and SI Appendix, Fig. S3). In
contrast, the mutant enzyme showed only limited resistance to
ciprofloxacin treatment (less than fivefold relative to WT),
consistent with the lack of cross-resistance observed in MIC
testing (Table 1). Similarly, we also designed and prepared other
mutant enzymes based on analysis of the structure (Fig. 3C),
namely E. coli GyrA-M26A and GyrA-I29V, equivalent to
S. aureus GyrA M27 and I30, respectively. These mutants displayed
no change in IC50 to ciprofloxacin and an approximately fivefold
increase in IC50 to compound 2 compared with WT (Table 2).
Compounds 1 and 2 Stabilize Both Single- and Double-Strand DNA-
Cleavage Complexes. Because compounds 1 and 2 bind away from
the site of DNA cleavage, we wanted to confirm that the DNA
R630E634
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Fig. 4. Polar interactions at the thiophene binding pocket of compound 2.
(A) Sequence alignment with S. aureus residue numbers above and E. coli numbers
below. (B) View of crystal structure of compound 2with S. aureusDNA gyrase and
DNA. Carbon atoms of compound 2 are in yellow, GyrB carbons in light pink, and
GyrA in cyan. A semitransparent (40%) surface is shown, with GyrB R630 and E634,
and GyrA P343 shown in stick (other residues as lines). Direct contacts between
compound and amino acid residues including via a water molecule (red sphere)
are shown by dotted lines. GyrB E634 in S. aureus is equivalent to E793 in E. coli.
The hydrophobic cavity is filled by a methyl group (*).
Table 1. Antimicrobial activity of thiophene inhibitors
Bacteria isolate
MIC, μg/mL
Compound 1 Compound 2 Ciprofloxacin
S. aureus OXFORD 32 8 0.125
S. pneumoniae ERY2 1 2 2
E. coli 7623 64 8 ≤0.008
E. coli 7623 ΔtolC 4 ≤0.125 ≤0.008
P. aeruginosa PAO1 >128 >128 0.125
P. aeruginosa PAO322 Δ(mexAB-oprM) Δ(mexCD-oprJ) Δ(mexEF-oprN) 16 8 ≤0.008
A. baumannii BM4454 NT 4 >8
A. baumannii BM4652 ΔadeABC ΔadeIJK NT 0.25 2
K. pneumoniae 1161486 NT 64 0.063
K. pneumoniae 1161486 GyrA S83I ParC S80I (FQr) NT 32 8
E. coli TOP10 ΔtolC 4 0.125 0.0005
E. coli W4753 ΔtolC GyrA S83L D87N ParC S80I ParE S458A (FQr) NT 0.063 8
E. coli TOP10 ΔtolC GyrB E793K 16 4 0.0005
MICs were determined against WT strains, efflux knockout mutants, fluoroquinolone-resistant strains, and a laboratory-generated,
thiophene-resistant GyrB E793K mutant of E. coli. A. baumannii, Acinetobacter baumannii; E. coli, Escherichia coli; FQr,
fluoroquinolone-resistant strain; K. pneumoniae, Klebsiella pneumoniae; NT, not tested; P. aeruginosa, Pseudomonas aeruginosa;
S. aureus, Staphylococcus aureus; S. pneumoniae, Streptococcus pneumoniae.
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cleavage detected in our experiments was due to the stabilization
of the covalently linked gyrase–DNA-cleavage complexes. After
denaturing the polypeptide chains using SDS, the chains can be
harvested from the phenol-buffer interface along with any DNA
to which they are covalently linked. The uncleaved DNA remains
in the aqueous layer whereas DNA covalently attached to the
denatured protein is enriched at the phenol-buffer interface and
can be recovered in the phenol fraction (28). As expected,
ciprofloxacin strongly induced double-stranded DNA cleavage as
shown by linear plasmid DNA extractible in the phenol (Fig. 5 B,
Right). Compound 2 induced a mixture of double- and single-strand
cleavage, both extractible in the phenol phase (Fig. 5 A and B, Left
and SI Appendix, Fig. S4), confirming that compound 2 stabilizes a
genuine cleavage complex in which the gyrase enzyme is covalently
linked to cleaved DNA. When DNA gyrase is submitted to the same
procedure of trapping the cleavage complexes followed by phenol
enrichment in the presence of only ATP, a lower baseline level of
single- and double-stranded cleavage is observed (Fig. 5C).
A similar experiment to that shown in Fig. 5A was performed
with varying the concentrations of ciprofloxacin (SI Appendix, Fig.
S5). Concentrations of compound 2 (0.8 μM) and ciprofloxacin
(0.16 μM) that produced the same overall extent of cleavage (i.e.,
the same amount of remaining intact plasmid) (SI Appendix, Fig.
S5) gave different levels of single- and double-stranded DNA.
Compound 2 stabilized 28% single-stranded DNA and 29%
double-stranded DNA whereas ciprofloxacin stabilized 3% single-
stranded DNA and 54% double-stranded DNA (SI Appendix, Fig.
S5). These results show that compound 2 stabilizes a higher level
of nicking compared with ciprofloxacin, which stabilizes mostly
double-strand cleavage. It is noteworthy that, to achieve the same
level of cleavage, roughly fivefold more of compound 2 is needed
compared with ciprofloxacin, despite the two compounds having
similar IC50 (SI Appendix, Fig. S5 and Discussion). It is possible
that some of the compound 2–gyrase–DNA ternary complexes do
not result in cleavage when trapped with SDS.
The DNA-Cleavage Sites Stabilized by Compound 2 Differ from Those
Stabilized by Ciprofloxacin. Upon low-resolution mapping of the
DNA-cleavage sites induced by compound 2 on plasmid pBR322,
we found that the cleavage sites observed in the presence of
compound 2 colocalized with cleavage sites trapped with the un-
inhibited enzyme, albeit with a different intensity (Fig. 6 A, Mid-
dle). This result is consistent with the crystal structure of
compound 2 (Fig. 3 E and F), which shows that the compound
does not make contact with the DNA. In contrast, the cleavage
site pattern induced by ciprofloxacin differs from that of the un-
inhibited enzyme (Fig. 6 A, Left), presumably because the cipro-
floxacin–gyrase complex has preferred DNA sequences that may
be different from the intrinsic DNA sequence preference of DNA
gyrase alone (29, 30). Our results (Fig. 6A) suggest that compound
2 does not change the preferred cleavage sites of the enzyme
whereas ciprofloxacin has different preferred cleavage sites.
Conversion of single-strand DNA breaks into double-strand
DNA breaks using nuclease S1 allowed the single- and double-
stranded DNA breaks stabilized by compound 2 to be visualized
on the same gel (Fig. 6 A, Right). We found that nuclease
S1 treatment merely increased the intensity of the cleavage
profile for compound 2 and did not produce new cleavage sites
(i.e., new double-stranded break sites) (Fig. 6 A, Right), which
suggests that the single-strand cleavage occurs at the same sites
as the double-strand cleavage, consistent with the hypothesis that
they are two products of the same event.
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Fig. 5. Compound 2 induces a mixture of single- and double-strand DNA
cleavage. (A) DNA-cleavage activity of compound 2 with WT E. coli gyrase
showing single- and double-stranded breaks (labeled as nicked and linear
DNA, respectively). (B) Both single- and double-strand cleavage induced by
compound 2 are trapped at a phenol-buffer interface (Left) and so is the
cleavage induced by ciprofloxacin (Right). Aq, DNA harvested from the
aqueous layer; Φ, DNA harvested from the phenol-buffer interface. Re-
actions run without ATP. (C ) ATP induces phenol-extractible, single- and
double-strand DNA cleavage by the unpoisoned E. coli DNA gyrase. Ap-
proximately five times more enzyme was used in the reactions compared
with B.
Table 2. Relative target activity of compound 2 and
ciprofloxacin against E. coli WT and thiophene-resistant mutant
gyrase protein
Compound
IC50 fold increase
WT GyrB E793K GyrA M26A GyrA I29V
2 1 >100 ∼5 ∼5
Ciprofloxacin 1 <5 1 1
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Kinetics of Cleavage Complex Formation Differs Between Compound
2 and Ciprofloxacin. We analyzed the kinetics of formation of the
cleavage complexes stabilized by compound 2 (Fig. 6B) and
found that maximum cleavage is achieved within 2 min with
compound 2 and that this timing is not influenced by ATP (SI
Appendix, Fig. S6). Importantly, the timing of the appearance of
the single- and double-strand cleavages is identical, and the ratio
between the two remains the same throughout the experiment,
which is in contrast to ciprofloxacin, which induces double-strand
cleavage with slower kinetics and through a detectable single-
strand intermediate, as reported previously (31). This rate of
cleavage with ciprofloxacin is further slowed when ATP is absent
(SI Appendix, Fig. S6).
Compound 2 Does Not Inhibit ADPNP-Induced Relaxation of Positively
Supercoiled DNA. When DNA gyrase acts on positively super-
coiled DNA, ATP binding results in efficient DNA capture,
strand passage (due to the presence of positive plectonemes),
and, ultimately, relaxation of the substrate DNA (32, 33). In
the presence of the nonhydrolyzable ATP analog 5′-adenylyl-
β,γ-imidodiphosphate (ADPNP), DNA gyrase can perform only
one round of relaxation on positively supercoiled DNA (32) (no-
compound controls in Fig. 7, Upper), and the amount of nicked
or linear DNA does not change noticeably after relaxation of the
positively supercoiled DNA (no-compound controls in Fig. 7,
Lower). In the presence of ciprofloxacin, the positively super-
coiled DNA is not fully relaxed (Fig. 7, Upper), and multiple
cleavage complexes are trapped on the DNA plasmid substrate
so it runs as a smear (Fig. 7, Lower). In the presence of com-
pound 2 and ADPNP, the positively supercoiled DNA substrate
is fully relaxed (Fig. 7, Upper), but much of the substrate DNA
plasmid has been converted into a linear or nicked form (Fig. 7,
Lower), suggesting that, although the DNA has passed through
the DNA gate, to formally relax the positively supercoiled DNA,
the DNA is still stabilized in a cleaved form.
Fig. 7 shows that compound 2 does not inhibit ADPNP-induced
relaxation of positively supercoiled pBR322 whereas ciprofloxacin
partially blocks this process. These results are consistent with
compound 2 blocking the resealing of the DNA only after strand
passage and not inhibiting the operation of the DNA gate whereas
the data with ciprofloxacin (which binds in the cleaved DNA)
suggest inhibition of strand passage.
Discussion
In this study, we detail the discovery and characterization of a class
of bacterial DNA gyrase inhibitors. Compound 1, identified via a
DNA gyrase-targeted HTS, was shown to have modest antibacterial
activity, albeit activity against WT Gram-negative pathogens was
limited due to penetration and/or efflux effects. Compound 1 was
shown to inhibit the supercoiling activity of DNA gyrase and to
stabilize DNA gyrase-dependent DNA cleavage. A crystal structure
showed that compound 1 bound to a previously unknown site on
gyrase remote from the catalytic DNA-cleavage site. The structural
information was used to design a modified inhibitor with a tighter fit
inside the pocket, resulting in compound 2, which had improved
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Fig. 6. A distinct cleavage mechanism for compound 2 compared with
ciprofloxacin. (A) Mapping of cleavage induced by ciprofloxacin and com-
pound 2 on plasmid pBR322. E. coli DNA gyrase cleavage products were
digested by EcoRI, separated by electrophoresis, transferred onto a nitro-
cellulose membrane, and probed with a short PCR fragment hybridizing next
to the EcoRI site, on one side only. (Left) The cleavage pattern differs be-
tween ciprofloxacin and compound 2. Arrows point at specific differences
between the two compounds. (Center) Cleavage observed in the absence
and presence of compound 2, respectively, showing similar cleavage pat-
terns. Six reactions were pooled for the “No compound” control to increase
the signal. (Right) Treatment by nuclease S1 (which degrades single-stranded
DNA and converts nicked plasmids into linear forms) (SI Appendix, Fig. S10)
does not change the profile. #, This band is strictly nuclease S1-dependent
and occurs with a much higher intensity with the uninhibited enzyme (SI
Appendix, Fig. S10). (B) Kinetics of DNA cleavage in the presence of E. coli
DNA gyrase and ciprofloxacin or compound 2. Cleavage reactions were
allowed to continue for the times indicated before trapping and separation
of the cleaved products by electrophoresis, followed by quantification. Data
were fitted using a simple kinetic scheme involving a single-strand in-
termediate for ciprofloxacin and to a single exponential for compound 2;
this line is indicative only.
Chan et al. PNAS | Published online May 15, 2017 | E4497
M
IC
RO
BI
O
LO
G
Y
CH
EM
IS
TR
Y
PN
A
S
PL
U
S
activity at both the target and whole cell level. Binding to this site
was confirmed to be relevant for inhibition of DNA gyrase by the
isolation and characterization of mutations in the binding site, which
showed resistance to compounds 1 and 2, but not to ciprofloxacin.
DNA gyrase enzymes with mutations in the binding site were
expressed and tested in vitro, showing decreased susceptibility to
compounds 1 and 2 but not to ciprofloxacin, further confirming the
relevance of this binding site. In contrast to ciprofloxacin, compound
2 does not change the preferred cleavage pattern of the uninhibited
enzyme nor does it inhibit the opening of the DNA gate.
Compound 2 inhibits negative supercoiling by E. coli DNA
gyrase as efficiently as ciprofloxacin (SI Appendix, Table S3) and is
less efficient in stabilizing cleavage than ciprofloxacin (SI Appen-
dix, Fig. S5). This apparent discrepancy can be explained by as-
suming that compound 2 has a high affinity for binding to gyrase
(similar to that of ciprofloxacin) but that DNA is not cleaved in
every ternary complex formed by compound 2 with the enzyme
and DNA. In other words, we propose that a pool of compound
2–enzyme–DNA complexes remain uncleaved whereas the cipro-
floxacin–enzyme–DNA complexes are primarily cleaved. Com-
pound 2 was also shown to stabilize both single- and double-strand
DNA breaks (Fig. 5 A and B and SI Appendix, Figs. S4 and S5).
The mixture of single- and double-strand DNA-cleavage com-
plexes observed distinguishes this class of compounds mechanis-
tically from the FQs. We found that ATP can also induce a
mixture of single- and double-strand breaks with the uninhibited
enzyme, albeit at much lower levels (Fig. 5C). In addition, com-
pound 2 induces a rapidly appearing (relative to ciprofloxacin)
cleavage profile similar to that observed with ATP-stimulated
cleavage, with single- and double-strand breaks arising together
at the same sites on DNA, which suggests that all strand breaks
with compound 2 arise from the trapping of specific and homo-
geneous cleavage complexes. Altogether, these results point to-
ward the idea that the thiophene compounds 1 and 2 allosterically
stabilize a DNA cleavage-competent conformation of gyrase that
resembles the cleavage-competent conformation transiently adop-
ted by the enzyme during its normal ATP-catalyzed strand passage
catalytic cycle. This cleavage-competent conformation presumably
affords some flexibility to the DNA gate consistent with the ob-
servations that (i) the DNA gate opening is unimpaired by binding
of compound 2 and (ii) a mixture of intact DNA and single- and
double-strand cleaved DNA molecules within the ternary complex
is formed by compound 2.
A structural hypothesis for the action of thiophene compounds 1
and 2 can be found by considering two structures of A. baumannii
topo IV: apo and in a complex with DNA and moxifloxacin (an FQ
related to ciprofloxacin). The thiophene compound-binding pocket
does not exist in a 2.2-Å apo A. baumannii crystal structure due to a
hinge movement around R33 of the ParC subunit (25), which moves
the TOPRIM domain relative to the WHD (SI Appendix, Figs.
S8 and S9). In apo bacterial type IIA topoisomerases, R33 is at the
C-terminal end of the Aα1 helix (SI Appendix, Fig. S8), and, in many
apo-bacterial topoisomerase structures, the N terminus of the
Aα1 helix is disordered, as are the Bα9 and Bα10 helices (e.g., ref.
15). The thiophene compound-binding pocket described here is not
observed in any apo bacterial topoisomerase II structure that we are
aware of. In complexes of bacterial topoisomerases with DNA,
R33 is no longer in the Aα1 helix (SI Appendix, Fig. S8), and the
peptide plane between residues 32 and 33 has rotated so that
R33 has phi–psi angles outside the normal regions of the Ram-
achandran plot (15). In eukaryotic type IIA topoisomerases, the
Aα1 helix does not act as a hinge; this difference may be due to the
insertion of an extra amino acid in bacterial sequences, just before
the conserved arginine (GyrA residue R33 in alignment in SI Ap-
pendix, Table S2). The residues lining the thiophene compound-
binding pocket are conserved among bacteria, perhaps because
the pocket needs to open and close during the bacterial catalytic
cycle, as observed when the two A. baumannii topo IV structures
are compared (SI Appendix, Figs. S8 and S9) (25). This finding
suggests that the opening and closing of this Aα1 hinge pocket may
be coupled to the binding, cleavage, religation, and release of DNA
from the DNA gate. The relative motion of the TOPRIM domain
and WHD within a covalently fused subunit (SI Appendix, Figs.
S8 and S9) can result in the opening and closing of the Aα1 hinge
pocket, and blocking this motion with inhibitors, such as compounds
1 and 2, can stabilize cleavage complexes.
We speculate that interfering with this movement inhibits reli-
gation by favoring a DNA cleavage-prone conformation. The
residues lining the pocket are almost completely conserved in key
bacterial pathogens (SI Appendix, Table S2); the only exception to
this residue conservation is in Mycobacterium tuberculosis gyrase,
where the residue equivalent to E634 (in S. aureus) is a threonine.
Recent crystal structures of M. tuberculosis gyrase with FQs (34)
show that the pocket described here is present; however, the
distinct shape of the pocket suggests that different compounds
may be required to exploit this pocket in M. tuberculosis gyrase.
Clinically proven targets for antibacterials are few in number,
and endeavors to find new ones making use of genomic in-
formation have proven challenging (20, 21). Producing new mol-
ecules against well-validated targets continues to be a successful
strategy for delivering new antibacterials for clinical trials. Although
we were unable to optimize the current series into a developable
drug, the thiophene-binding pocket described here constitutes a
unique way of targeting DNA gyrase, corrupting the enzyme into a
DNA-cleavage complex with toxic results for the pathogen. Its
mechanism of action bypasses existing target-mediated resistance to
2
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Fig. 7. Compound 2 does not inhibit ADPNP-induced relaxation of posi-
tively supercoiled DNA by E. coli DNA gyrase. Reactions containing gyrase,
the indicated compounds (at 4 μM) ± nucleotide were carried out with
positively supercoiled DNA (see Materials and Methods for details). (Upper)
After relaxation, cleavage complexes were removed from the DNA by se-
quential addition of EDTA and proteinase K to the reaction (this procedure
fully reverses the cleavage induced by both compounds—tested in-
dependently on relaxed DNA) (SI Appendix, Fig. S7). Rel, relaxed DNA, +SC,
positively supercoiled DNA. (Lower) After relaxation, cleavage complexes
were trapped on the DNA by the addition of SDS to identical reactions as in
Upper. The gel in Lower was run in the presence of 0.5 μg/mL ethidium
bromide (see Materials and Methods for details). Asterisk denotes multiple
cleavage events resulted in the smearing of the DNA substrate on the gel.
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gyrase-targeting antibiotics currently in clinical use. Moreover, we
have found that the frequency of resistance was low, suggesting
either that the residues involved in the binding of the thiophenes are
important for the enzyme function and/or that the pocket is small
enough that the number of mutable residues is limited. These
features make this allosteric pocket a possible target for the design
and development of antibacterials with a potential broad-spectrum
against Gram-negative bacteria.
Materials and Methods
Chemistry. Compounds 1 and 2were synthesized as described in SI Appendix,
Supporting Materials and Methods.
Crystallography. Proteins were purified and complexes were prepared and
crystallized and structures were determined using methods as previously de-
scribed (19, 24). The X-ray data collection (35) and refinement statistics for the
two thiophene structures described in this paper are shown in SI Appendix,
Table S1. More details of the crystallization and structure determinations are
given below. Structural figures were drawn with Pymol (36).
Compound 1. For crystallization, 1 μL of complex [0.035 mM GyrB27A56(GKdel/
Tyr123Phe) dimer, 0.174 mM 20-12p-8 DNA duplex (24), 2.2 mM compound 1,
4.3 mMMnCl2, 4.3% DMSO, 17 mM Hepes, 87 mM Na2SO4, pH 7.0] was mixed
with 1 μL of crystallization buffer (11% PEG 5000 MME, 150 mM Bis-Tris, pH
6.2). The 1.98-Å structure was determined by molecular replacement and re-
fined using Refmac (37) and Phenix-refine (38); the structure was rebuilt with
coot (39). The structure was twinned with refined twin fractions of 0.76/0.24.
The structure contained two complexes in the asymmetric, each with two
molecules of compound 1 bound. The central four base pairs of DNA, between
the two DNA-cleavage sites, were largely disordered, as in a binary complex,
with the same doubly nicked DNA duplex (19). The complex with compound 1
was in a very similar cell to a previously determined structure of S. aureus DNA
gyrase with ciprofloxacin and DNA (PDB ID code 2XCT; cell P21 89.0 123.2
170.4, beta = 90.25° compared with compound 1 cell, P21 89.4 120.7 168.9,
beta = 90.0°), suggesting that compound 1 and ciprofloxacin can stabilize
similar conformations of the enzyme.
Compound 2 (soaked into GSK945237 cocrystal). In all our previous complex
structures of S. aureus DNA gyrase with DNA and a variety of DNA-gate in-
hibitors (15, 19, 40), the thiophene class inhibitor-binding pocket was present.
Therefore, a soakable crystal system for determining thiophene crystal struc-
tures was developed by cocrystallizing with an NBTI (namely, GSK945237) (41)
and then soaking in compound 2. For crystallization, 1 μL of complex
[0.047 mM GyrB27A56(GKdel) dimer, 0.072 mM 20-12p-8 DNA duplex,
0.36 mM GSK945237, 2.7 mM MnCl2, 3.6% DMSO, 18.6 mM Hepes, 54 mM
Na2SO4, pH 7.0] was mixed with 1 μL of crystallization buffer (7–11% PEG 5000
MME, 130 to 190 mM Bis-Tris, pH 6.2) and streak seeded before covering with
paraffin oil. A hexagonal cocrystal with GSK945237 was transferred into a
cryo-buffer containing compound 2 (15% glycerol, 20% PEG 5000 MME,
110 mM BisTris, pH 6.2, 2 mM compound 2) and soaked for 4 h at room
temperature before being frozen in liquid nitrogen. The structure was refined
using Refmac (37) and Phenix-refine (38) from related structures in the same
space group (15), and rebuilding was carried out with coot (39). The structure
contains one complex in the asymmetric with two molecules of compound 2
bound, and one GSK945237 sitting on the internal twofold axis of the com-
plex. The central four base pairs of DNA, between the two DNA-cleavage sites,
were well-ordered, with the left-hand side of GSK945237 sitting between the
central bases of the DNA as in other NBTI structures (15, 40). Tyr-639 from the
GyrB subunit was displaced from the thiophene-hinge pocket by the binding
of compound 2.
In Vitro Topoisomerase Assays. DNA cleavage and topoisomerase activity
assays were performed as described (19). For cleavage site mapping, the DNA
material from a cleavage assay was purified by phenol extraction and eth-
anol precipitation in the presence of 150 mM NaCl to remove the SDS. The
pellet was resuspended in water and digested by EcoRI (New England Biol-
abs) according to the manufacturer’s instructions. The samples were then
ethanol-precipitated and analyzed by electrophoresis on a 1% agarose gel
containing 0.5 μg/mL ethidium bromide, followed by DNA transfer onto a
Hybond-N membrane (GE Life Sciences) according to the manufacturer’s
recommendations. The DNA was detected by hybridization to a 100-bp PCR
fragment (oligo forward, AGCTTTAATGCGGTAGGCATAGG; oligo reverse,
TGGCGATGCTGTCGGAATG) labeled by random priming in the presence of
32P-labeled dATP (Thermofisher random priming labeling kit) according to
the manufacturer’s instructions. Nuclease S1 (New England Biolabs) treat-
ments were carried out according to the manufacturer’s instructions just
after the first ethanol precipitation. Subsequently, an additional phenol
extraction and a PCR purification procedure (Qiagen) were performed be-
fore the EcoRI digestion. An aliquot of the untreated (undigested by EcoRI)
sample was analyzed separately on an agarose gel to assess the conversion
of the nicked plasmid into a linear form (compared with no S1 treatment).
For the ADPNP-induced relaxation of positively supercoiled DNA, 250 ng of
positively supercoiled pBR322 (see below) was incubated in the presence of
∼4 μg of A2B2 E. coli DNA gyrase using the same buffer as for the cleavage
assays. To this reaction, 1 mM ADPNP (Sigma) and/or 4 μM either compound
2 or ciprofloxacin was added. The mixture was incubated for 30 min at 37 °C
and either trapped by SDS as in the cleavage assay (treatment 1) (SI Ap-
pendix, Fig. S7) or treated by 8 mM EDTA followed by the addition of 20 μg
of proteinase K (treatment 3) (SI Appendix, Fig. S7). Treatment 3 resulted in
the complete reversal of all cleavage complexes (SI Appendix, Fig. S7), re-
vealing the topology of the substrate DNA plasmid (Fig. 7). Treatment
1 resulted in the entrapment of the cleavage complexes in the form of ir-
reversible DNA cleavage that could be visualized by an agarose gel con-
taining ethidium bromide (Fig. 7, Lower).
Preparation of Positively Supercoiled DNA. Relaxed pBR322 was incubated for
30 min at 37 °C with 4 μg of A2B2 E. coli DNA gyrase in a cleavage assay in the
absence of ATP. The enzyme constrained positive writhing through its
binding to the DNA substrate. The intrinsic relaxation activity of the enzyme
removed the compensatory negative writhing, thereby introducing net
positive supercoiling. The reaction was stopped with treatment 1 (above).
The DNA was purified by ethanol precipitation, followed by a PCR purifi-
cation column (Qiagen). The DNA was eluted in ultrapure water. The
handedness of the supercoiling was ascertained by migration on a chloro-
quine agarose gel.
Purification of E. coli DNA Gyrase. GyrA and GyrB subunits were expressed in
E. coli and purified separately as described previously (42).
MIC Assays. Antibacterial MIC assays were determined according to Clinical
and Laboratory Standards Institute guidelines (43).
Resistant Mutant Isolation. Bacterial cells were plated onto Müller–Hinton agar
plates containing 2× or 4× above the MIC of the thiophene inhibitor. After 48 h
incubation at 37 °C, resistant colonies were purified on compound containing
plates and then on plates without compound. The quinolone resistance-
determining region or full length of gyrA/B was amplified by PCR from the re-
sistant mutants, and DNA was sequenced using the following forward and reverse
primer pairs (all 5′ to 3′): for E. coli gyrA, GAACTCACCTTCCAGATCCCA and
TCGGCGCATGACGGATCAGTTC; and gyrB, CGCTGGACTGGCTGGTGAAAGAG and
GCCCTTTTCTTATAGCTTCTTGC; for K. pneumoniae gyrA, CGATTTCGTCGAC-
AACTATG and GGTTATGTGGCGGTATGTTG; and gyrB, TCTCCATCCAGCGCTATA-
AAGG and AGCAGCGGATTCCTCTTTTAGC; for A. baumannii gyrA, GGAAG-
ATAACTACGACGGTT and GCCATACCTACAGCAATACC; and gyrB, AAAGGT-
CTGGGCGAGATGAATGC and CTAAAGCCGCACATGAAATCAGC. Mutations in
thiophene-resistant transformants were confirmed by PCR and DNA se-
quence analysis.
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